Motilal Oswal Raises Sagility India Target Price, Projects 17% Revenue and EBITDA CAGR on Q2 Beat

The Quick Take

• Motilal Oswal upgraded its Sagility India price target following Q2 results, projecting a 17% compound annual growth rate in revenue, EBITDA and profit after tax.
• Growth drivers include increased volumes from top healthcare clients, new logo additions, cross-selling initiatives and M&A synergy realization.
• Sagility India focused on US healthcare payer and provider outsourcing is well positioned to benefit from ongoing cost pressure in the American healthcare system.

Motilal Oswal target price upgrade for Sagility following Q2 results reflects confidence that the healthcare IT services company growth drivers are materializing on the expected schedule. A 17% compound annual growth rate across revenue, EBITDA and profit after tax is an ambitious target for an IT services company in the mature healthcare BPO and technology segment, but it is supported by favorable structural dynamics. U.S. healthcare payers and providers face sustained cost pressure making outsourcing of claims processing, member management and clinical support functions structurally attractive over the medium term.

The four growth vectors Motilal cites represent different risk and execution profiles that investors should assess separately. Existing client volume increases are the most predictable and lowest-risk source given established relationship continuity. New logo additions are the riskiest but highest-margin source when successfully converted after a sales process. Cross-selling between legacy and acquired capabilities requires coordinated sales execution that takes time to implement at scale. M&A synergy realization is contingent on successful post-merger integration of processes, systems and personnel.

Watch for Sagility next quarterly update on client concentration metrics: if top-five clients represent more than 50% of revenue then the 17% CAGR depends critically on those specific relationships expanding without disruption. Also monitor the U.S. healthcare regulatory environment particularly CMS reimbursement rate decisions for Medicare Advantage plans which directly affect the spending capacity of Sagility largest payer clients. The FY2028 free-cash-flow generation will be the definitive multi-year test of whether the projected growth CAGR converts to shareholder value.

Synthesized from 1 source.